- Markets
- Healthcare
- BIOFILCHEM
BIOFILCHEM
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
This data is currently unavailable for this company.
Events:
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Biofil Chem & Pharma do?
Biofil Chemicals & Pharmaceuticals Ltd. specializes in manufacturing a variety of drugs, including anti-bacterial, analgesics, anti-malarial, and more. They also export their products to multiple countries.
Who are the competitors of Biofil Chem & Pharma?
Biofil Chem & Pharma major competitors are Achyut Healthcare, Ind-Swift, Makers Laboratories, JFL Life Sciences, Bharat Immunological, Deccan Health Care, Dipna Pharma.. Market Cap of Biofil Chem & Pharma is ₹78 Crs. While the median market cap of its peers are ₹71 Crs.
Is Biofil Chem & Pharma financially stable compared to its competitors?
Biofil Chem & Pharma seems to be less financially stable compared to its competitors. Altman Z score of Biofil Chem & Pharma is 2.77 and is ranked 4 out of its 8 competitors.
Does Biofil Chem & Pharma pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Biofil Chem & Pharma latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Biofil Chem & Pharma allocated its funds?
Companies resources are allocated to majorly unproductive assets like Accounts Receivable
How strong is Biofil Chem & Pharma balance sheet?
Balance sheet of Biofil Chem & Pharma is moderately strong.
Is the profitablity of Biofil Chem & Pharma improving?
The profit is oscillating. The profit of Biofil Chem & Pharma is ₹0.6 Crs for TTM, ₹0.71 Crs for Mar 2024 and ₹0.56 Crs for Mar 2023.
Is the debt of Biofil Chem & Pharma increasing or decreasing?
Yes, The debt of Biofil Chem & Pharma is increasing. Latest debt of Biofil Chem & Pharma is ₹0.23 Crs as of Sep-24. This is greater than Mar-24 when it was -₹4.04 Crs.
Is Biofil Chem & Pharma stock expensive?
Biofil Chem & Pharma is expensive when considering the EV/EBIDTA, however latest PE is < 3 yr avg PE. Latest PE of Biofil Chem & Pharma is 128, while 3 year average PE is 158. Also latest EV/EBITDA of Biofil Chem & Pharma is 110 while 3yr average is 93.5.
Has the share price of Biofil Chem & Pharma grown faster than its competition?
Biofil Chem & Pharma has given lower returns compared to its competitors. Biofil Chem & Pharma has grown at ~3.83% over the last 2yrs while peers have grown at a median rate of 15.04%
Is the promoter bullish about Biofil Chem & Pharma?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Biofil Chem & Pharma is 46.82% and last quarter promoter holding is 46.82%.
Are mutual funds buying/selling Biofil Chem & Pharma?
There is Insufficient data to gauge this.